Molecular Microbiology Research, 2025, Vol.15, No.2, 93-99 http://microbescipublisher.com/index.php/mmr 97 7 Clinical Applications and Recent Advances Successful translation tends to follow a simple triad: a clearly framed indication, a plausible microbial lever, and a delivery plan that reaches the pathological niche with measurable effect. Readouts should privilege objective biology over sentiment-biomarkers and tissue findings before questionnaires-so that enthusiasm does not outrun evidence. 7.1 Gastrointestinal diseases For recurrent ‘Clostridioides difficile’ infection, fecal microbiota transplantation (FMT) continues to provide the most decisive signal; a well-screened ecological reset can restore colonization resistance when donor selection and manufacturing remain rigorous (Zmora et al., 2019; Kamath et al., 2025). Route choice-capsule versus colonoscopy-mostly reflects logistics and patient factors, whereas quality control governs biological benefit. In IBD and IBS, broad “good-bug” supplementation is less defensible than targeted interventions that align with identifiable deficits: barrier repair, short-chain-fatty-acid replenishment, or subtraction of pathobionts with phage-based approaches (Han et al., 2024; Li et al., 2024). Encapsulation and colon-triggered release are not cosmetic features; raising viable counts at inflamed mucosa is associated with improvements in fecal calprotectin and endoscopic healing, not merely symptom scores (Li et al., 2024; Kamath et al., 2025). A practical rule holds: route is logistics; delivery design is biology. Two operational details improve outcomes in practice. First, antibiotic stewardship around the intervention prevents unintentional “scorched earth” effects that blunt engraftment. Second, pairing a candidate strain with a compatible prebiotic can function as an “engraftment primer,” especially when baseline diets are low in fermentable fiber. Both measures sit comfortably alongside standard care and do not complicate safety monitoring. 7.2 Metabolic diseases allergic diseases Efficacy rises when strain and pathway align-Akkermansia with mucin/bile-acid signaling; Faecalibacterium with butyrate and insulin sensitivity (O'Toole et al., 2017; Han et al., 2024). Persistence beats dose; enteric protection and microencapsulation earn their place. Cue-sensing engineered strains are coherent but need stratified cohorts by diet, baseline microbiome, and immune context (Juarez et al., 2022; Fooladi et al., 2023). In allergy/autoimmunity, the correct bar is durable tolerance rather than transient symptom relief. 7.3 Cancer therapy and immune modulation Oncology is an address problem first. Bacteria and nano-biohybrids exploit hypoxia and acidity to dwell in tumors, where stimulus-responsive release confines cytotoxics or immune agonists; route (intratumoral vs. intravenous) follows anatomy, not doctrine (Cao and Liu, 2020; Ali et al., 2024). Combining microbial products or defined LBPs with checkpoint blockade is reasonable when layered safeguards-genetic and physical-keep risk contained. 8 Challenges and Future Perspectives The familiar red flags persist: infection risk, horizontal gene transfer, and unintended immune reactions. Hence the emphasis on containment and layered control (Mimee et al., 2016; Fooladi et al., 2023). Regulation and ethics travel alongside, especially with GMOs. Effectiveness varies with microbiome composition, genetics, and environment, pushing us toward profiling-guided, tailored consortia (Kamath et al., 2025). Biosensing, smart carriers, and gene circuits promise on-demand release aligned with precision-medicine goals (Feng et al., 2022; Ali et al., 2024). For scale-up, standardization and quality control remain the chokepoints-particularly for encapsulated live products (Charbonneau et al., 2020; Kamath et al., 2025). Costs and equitable access matter too. The likely trajectory is tighter integration of engineered microbes with nanotechnology and responsive carriers to sharpen targeting and broaden indications (Lin et al., 2021). 9 Conclusion The field is moving quickly. Probiotics, next-generation strains, engineered bacteria, and FMT already form a
RkJQdWJsaXNoZXIy MjQ4ODYzNA==